Preparing Emerging Biotechs For The Best Deals – Insider Insights
As the market for pharma and biotech deal making heats up in 2018, Scrip looks at the process of valuing novel companies with emerging data and collects best advice from experts on how start-ups should pitch to potential pharma partners.
You may also be interested in...
Biopharma executives and investors gathered in San Diego on Feb. 28 and March 1 to talk about finding and funding innovation with a focus on novel technology and artificial intelligence that can improve drug discovery and development success rates.
AstraZeneca takes second license of antisense candidate under 2012 pact with Ionis, this time for kidney disease. Aldeyra is working with J&J on novel immune-modulating drugs for systemic inflammatory conditions.
It is time for In Vivo's 13th annual Deals of the Year contest. We've selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners.